US Food and Drug Administration US FDA has successfully completed the inspection of the multipurpose API manufacturing facility of Solara Active Pharma Scienc
The US Food and Drug Administration (FDA) completes inspection of Solara Active Pharma Sciences API manufacturing facility in Visakhapatnam, Andhra Pradesh, with no observations. Solara confirms compliance with FDA standards. The facility, dedicated to Ibuprofen API production, marks Solara s second successful FDA inspection. The company aims for global market expansion with FDA-approved facilities.
Adani Wilmar has delivered strong double-digit volume growth at 25% for the first quarter ended June. However, sales declined 15%, mainly due to sharp drop in edible oil prices.